GLP-1 access guide
How much does compounded tirzepatide cost per month?
Published calendar-month compounded tirzepatide injection charges range from $169 to $348 across 6 providers in our directory; four-week charges range from $299 to $359 across 2 other providers, checked 2026-10-02–2026-10-05. Dose coverage and included services differ, and these published charges exclude unresolved fees and exit costs. [4][5][8][9]
Why the starting amount may not apply to your quote
A plan can publish one amount for a stated range and a different amount for another range. The lowest advertised amount therefore needs its dose coverage attached. Compare a documented range with the scenario a clinician has actually prescribed; do not assume that an unspecified starting offer covers every weekly injection amount. This guide covers price interpretation, not which dose to use. [1]
The injection examples exclude oral, sublingual and microdose offers. Those products cannot be substituted into the same price comparison just because a page uses the word tirzepatide. We also do not use unknown-dose coverage to establish a standard-dose headline. A missing comparable record means the published evidence is insufficient, not that the company necessarily refuses to serve you. [1]
Read the recurring payment and the commitment together
A low monthly equivalent can describe a larger prepaid purchase. Ask how much leaves your account on enrollment, how often another payment is due, and whether the plan automatically renews. A six-month total divided by six may be useful for one calculation, but it does not describe a cancel-anytime monthly bill. FTC consumer guidance recommends checking renewal and cancellation terms before joining a subscription. [2]
For a monthly plan with a minimum term, the first 12 weeks of payments may leave additional obligations. For a prepaid plan, money for a longer term may be charged within the first 12 weeks. Treat those situations separately. Our comparison counts the scheduled payments in its example and identifies unresolved exit terms rather than pretending the financial scenarios are identical. [2]
Budget for changes the headline does not resolve
Request an itemized statement of medication, clinical access, membership, shipping, lab requirements and any tax. Then ask whether an introductory payment replaces an ordinary bill or is an additional charge. A discount can be real while still failing to establish the ongoing price. Record its eligibility and number of qualifying fills alongside the amount. [2]
Use the full evidence table for commitments and source dates, then confirm the current quote directly. An offer last checked earlier in the month is not a live inventory or checkout confirmation. The comparison’s price order uses published 84-day payments and excludes unresolved charges; it cannot determine the cheapest exit-inclusive treatment program. [2]
Flat rates and dose bands tell different cost stories
The tirzepatide records include both a flat published program price and providers that divide coverage into price bands. Gentle’s lower record covers its stated starting range, while its other rows cover higher ranges at different recurring amounts. Cora instead publishes a flat ingredient-specific plan across documented doses. A single “tirzepatide monthly cost” cannot faithfully summarize those two designs. The useful answer is the dated range plus the row that covers the proposed prescription. A patient at another band should not assume that the minimum range endpoint is available for that prescription. [4][7]
The same issue affects a provider’s claim that all doses have one price: it is a statement about the published billing policy, not a promise that every dose is available to every patient. Our financial comparisons preserve the provider’s policy and compare it with the stated ranges of other offers. They do not turn a pricing phrase into treatment instructions. Keep prescription eligibility with the clinical team, and use the table to answer how the advertised bill is structured once a specific prescription scenario is being considered. [7][1]
Separate the recurring bill from the first-payment calculation
Found and Pallas have catalog records for a documented introductory charge replacement. Their ordinary four-week amounts and their first charges are therefore separate facts. The comparison applies the replacement only where the audit is tied to the source, ordinary recurring amount and billing period. An introductory price is not deducted indiscriminately from every offer. This gives you a way to inspect why a first-payment example differs from the recurring table without assuming a coupon applies to a plan or dose that its source never identifies. [8][9]
A 12-week sum is not the amount to enter automatically for a year. Monthly plans use calendar billing dates; four-week plans use 28-day cycles. A prepaid term uses a larger payment when it is collected, even when the purchased period extends past 84 days. The comparison therefore preserves the actual payment mechanism instead of smoothing every plan into a monthly average. If you are deciding between a recurring and a term purchase, examine both the first bill and the commitment as well as the 12-week subtotal. [6][7]
Why the range leaves out some offers
Mixed-cadence components are another source of apparently low prices. TOM has records that separate a calendar-month program fee from a medication amount billed every four weeks. Those components do not form one exact recurring monthly quote, even if a marketing page presents them near each other. They can still be modeled in a dated payment scenario, but the combined-payment range in the direct answer excludes them. That avoids describing two clocks as one flat bill. Read the full provider pricing record when a plan uses this structure. [10]
Before paying, confirm the dose coverage, pharmacy product and financial term of the selected record. For a longer prepaid term, use the annual-plan guide; for cancellation and refill details, use the signup checklist. FDA’s post-shortage compounding requirements are a separate issue from the price calculation. An advertised amount does not resolve whether the particular prescription and pharmacy transaction satisfy those conditions. A provider’s explanation should be attributed as its explanation rather than treated as a legal conclusion from this directory. [3][2]
Published provider prices in our directory
These injection records come from our provider catalog. Each retains its dose coverage, actual billing period and original price-check date. They are published charges, with unresolved fees and commitments excluded; confirm the checkout quote before paying. Rows run from lower to higher displayed charge within each billing period.
Compounded tirzepatide
| Provider / plan | Published recurring charge | Dose coverage | Checked / primary sources |
|---|---|---|---|
| Gentle Health Compounded tirzepatide injection, monthly subscription | $169 / 1 month Unresolved costs: see provider record. | 2.5–5 mg/week (starting) | |
| Gentle Health Compounded tirzepatide injection, monthly subscription | $219 / 1 month Unresolved costs: see provider record. | More than 5 mg up to 10 mg/week | |
| Cora Health Compounded tirzepatide, monthly plan | $225 / 1 month Unresolved costs: see provider record. | Any dose (Cora charges the same price at every dose) | |
| Trimi Monthly plan | $235 / 1 month Unresolved costs: see provider record. | Any prescribed dose | |
| TOM Weight Loss Tirzepatide plan (Premium membership) | $249 / 1 month Unresolved costs: see provider record. | Up to 15 mg weekly | |
| Gentle Health Compounded tirzepatide injection, monthly subscription | $269 / 1 month Unresolved costs: see provider record. | More than 10 mg up to 15 mg/week | |
| Shed 1-month plan | $299 / 1 month Unresolved costs: see provider record. | Any prescribed dose | |
| Lemonaid Health Month-to-month membership; medication billed separately each month | $348 / 1 month Unresolved costs: see provider record. | Any prescribed dose |
| Provider / plan | Published recurring charge | Dose coverage | Checked / primary sources |
|---|---|---|---|
| Pallas Health Monthly plan (4-week billing) | $299 / 4 weeks Unresolved costs: see provider record. | Any dose | |
| Found Compounded tirzepatide all-in plan, 1-month cash-pay term | $359 / 4 weeks Unresolved costs: see provider record. | Any dose (Found says the price is the same at every dose) |
Additional reading from a provider
These pages describe a provider’s perspective or its own service. The official documents cited in this guide establish regulatory, approval and program facts.
- Gentle Health: yearly budgeting (provider-authored; price observations September 15, 2026)
A provider-authored annual budget discussion that keeps compounded and branded tirzepatide transactions separate.
Checked
Sources
Sources are checked on the dates shown. Official documents establish product and program rules; provider sources describe their own offers and the additional reading identified above. Provider catalog examples retain their original price-check dates; this article’s preparation date does not refresh them.
- FDA: unapproved GLP-1 drugs — checked .
- FTC: trials, automatic renewals and subscriptions — checked .
- FDA: compounding policies as GLP-1 supply stabilizes — checked .
- gentle.health — pricing and FAQ — checked .
- www.lemonaidhealth.com — services/weight-loss — checked .
- trytrimi.com — pricing and FAQ — checked .
- www.trycora.io — plans — checked .
- joinfound.com — store/compounded-semaglutide — checked .
- www.pallashealth.co — treatments/glp-1 — checked .
- www.tomweightloss.com — pricing — checked .
- Gentle Health: yearly budgeting (provider-authored; price observations September 15, 2026) — checked .